Current Edition

news

Immatics Enters into a Strategic Partnership with Genmab to Develop Next Generation Bispecific Cancer Immunotherapies

Immatics and Genmab to Combine Proprietary Technologies to Create Transformative Bispecific Therapies against Novel, Proprietary Tumor Targets Immatics to Receive $54 Million Upfront, Milestone Payments …

Continue Reading →